These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 12566817

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
    Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA.
    Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D.
    Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
    [Abstract] [Full Text] [Related]

  • 7. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
    Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D.
    Int J Cancer; 2005 Dec 10; 117(5):825-30. PubMed ID: 15957165
    [Abstract] [Full Text] [Related]

  • 8. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y, Pinedo IR, Tapuria N, Zabron A, Davidson BR.
    Eur J Gastroenterol Hepatol; 2008 Oct 10; 20(10):1006-11. PubMed ID: 18787469
    [Abstract] [Full Text] [Related]

  • 9. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999 Oct 10; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enzyme Kinetic Assay to Measure the Activity of Tumor M2 Pyruvate Kinase in Breast Cancer Patients.
    Guan M, Tong Y, Liu X, Dong D, Zhou Y.
    Ann Clin Lab Sci; 2017 Nov 10; 47(6):676-686. PubMed ID: 29263041
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
    Mulder SA, van Leerdam ME, van Vuuren AJ, Francke J, van Toorenenbergen AW, Kuipers EJ, Ouwendijk RJ.
    Eur J Gastroenterol Hepatol; 2007 Oct 10; 19(10):878-82. PubMed ID: 17873612
    [Abstract] [Full Text] [Related]

  • 15. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999 Oct 10; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 16. Serum tumour M2-pyruvate kinase as a biomarker for diagnosis and prognosis of early-stage non-small cell lung cancer.
    Xu C, Liu W, Li L, Wang Y, Yuan Q.
    J Cell Mol Med; 2021 Aug 10; 25(15):7335-7341. PubMed ID: 34255923
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
    Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S, Seiffert UB.
    Anticancer Res; 1997 Aug 10; 17(4B):3031-3. PubMed ID: 9329593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.